Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jenna Pawloski

Nurse Practitioner, Family Utica, NY Nurse Practitioner

NPI 1659866754 CMS profile 11183998

6 Rhoads Dr, Utica, NY 13502

Open in the dashboard

General payments

$62,049

977 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jenna Pawloski of Utica, NY is reported in the CMS Open Payments database as having received $62,049 across 977 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,518 185
2024 General $15,667 244
2023 General $14,453 166
2022 General $13,673 185
2021 General $10,739 197

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jenna Pawloski
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Jenna Pawloski were reported at $7,518. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Jenna Pawloski Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $10,739 $124 $35–$379 $132
2022 $13,673 $141 $44–$430 $149
2023 $14,453 $154 $49–$476 $160
2024 $15,667 $165 $51–$504 $164
2025 $7,518 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $37,999 133 payments
  2. Sun Pharmaceutical Industries Inc. $6,108 57 payments
  3. AbbVie, Inc. $4,580 146 payments
  4. Janssen Biotech, Inc. $3,883 111 payments
  5. UCB, Inc. $1,422 22 payments
  6. Incyte Corporation $1,321 89 payments
  7. Dermavant Sciences, Inc. $985 77 payments
  8. Galderma Laboratories, L.P. $809 62 payments
  9. Pfizer Inc. $774 40 payments
  10. LEO Pharma Inc. $713 45 payments
  11. Other $3,456 195 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $35,437 48 payments
  2. Food and Beverage $15,041 893 payments
  3. Consulting Fee $4,803 5 payments
  4. Honoraria $3,900 3 payments
  5. Travel and Lodging $2,013 17 payments
  6. Education $855 11 payments
Products named General payments · program years 2021–2025
  1. Otezla $28,368 109 payments
  2. ILUMYA $5,775 50 payments
  3. TREMFYA $3,698 94 payments
  4. SKYRIZI $2,646 93 payments
  5. Bimzelx $1,311 7 payments
  6. OPZELURA $1,231 88 payments
  7. VTAMA $1,099 90 payments
  8. SOTYKTU $653 39 payments
  9. CIBINQO $653 33 payments
  10. TALTZ $560 28 payments
  11. Other $6,558 424 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,025

Median for Nurse Practitioner: 389

Drug cost

$400,257

Median for Nurse Practitioner: $21,885

Branded share of claims

7.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 55 $210,617
Otezla Apremilast Brand 21 $162,554
Clobetasol Propionate Generic 156 $7,459
Betamethasone Dipropionate Generic 75 $3,391
Fluorouracil Generic 44 $3,335
Tacrolimus Generic 29 $2,479
Metronidazole Generic 28 $2,119
Imiquimod Generic 56 $1,542
Clindamycin Phosphate Generic 37 $1,442
Triamcinolone Acetonide Generic 175 $1,295

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$118,547

Of which drugs: $16,327

Medicare patients

474

Average age 74

Services billed

6,993

258 women, 216 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 39%
Diabetes 25%
Ischemic heart disease 21%
Atrial fibrillation 20%
Cancer 20%
Chronic kidney disease 18%
Depression 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 15 4,200 $5,667

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Otezla
$8,967 21 —
TREMFYA
$1,348 — —
Bimzelx
$1,225 — —
SKYRIZI
$453 — —
VTAMA
$388 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

977 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record